Analyst Serge Belanger of Needham maintained a Buy rating on Esperion, retaining the price target of $4.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Serge Belanger has given his Buy rating due to a combination of factors including Esperion’s strong financial performance and future growth potential. The company reported a significant increase in revenue for the third quarter of 2025, surpassing market expectations. This growth was largely driven by collaboration revenues, which showed a notable increase compared to the previous quarter and year.
Despite a slight miss in U.S. sales of Nexletol/Nexlizet, which was attributed to one-time charges, the overall outlook remains positive. The expected continued prescription growth and improved payer coverage are anticipated to bolster future sales. Additionally, the upcoming milestone payment from Otstuka further supports the company’s financial health and growth prospects, justifying the Buy rating.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $16.00 price target.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ESPR in relation to earlier this year.